New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies…
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity…
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab…
Research explores treatment patterns and health outcomes to inform and improve patient careBOSTON & SAN DIEGO--(BUSINESS WIRE)--Ontada®, a McKesson business…
NEW YORK, Dec. 6, 2024 /PRNewswire/ -- This December, Mount Sinai Hospital's Department of Urology, under the leadership of Ash…
STOCKHOLM, Dec. 6, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that discrete proton arc optimization in…
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the…
MIAMI, Dec. 6, 2024 /PRNewswire/ -- eMerge Americas, the premier global technology conference and expo shaping the future of tech, is…
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of…